Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
Holding PHVS?
Track your performance easily
PHVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.00 - $33.00
Previous Close$20.51
Volume53.76K
Average Volume (3M)102.86K
Market Cap
$1.11B
Enterprise Value$693.23M
Total Cash (Recent Filing)€391.23M
Total Debt (Recent Filing)€238.91K
Price to Earnings (P/E)―
Beta-2.33
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding52,290,212
10 Day Avg. Volume40,205
30 Day Avg. Volume102,860
Standard Deviation0.70
R-Squared0.05
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)2.79
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.29Price Target Upside72.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Pharvaris News
PremiumCompany Announcements
Pharvaris Advances in HAE Treatment with Strong Financials
PremiumCompany Announcements
Pharvaris CBO Resigns, Team Absorbs Duties
PremiumCompany Announcements
Pharvaris Refines License Terms with BRAIN BiotechBulls Say, Bears Say
Bulls Say
Market PotentialDespite entrenched competition in hereditary angioedema treatments, deucrictibant's unique profile and efficacy could lead to blockbuster sales and significant market share gains.
Patient Experience And AdherencePhysicians believe that oral options like deucrictibant could improve adherence and quality of life for patients, especially those who are needle-phobic or feel embarrassed using injectable treatments outside the home.
Treatment Efficacy And ConvenienceThe company's oral treatment for hereditary angioedema, deucrictibant, offers injectable-like efficacy and significant convenience as an oral pill, potentially transforming patient care.
Bears Say
Clinical DataClinical updates largely in-line with previous phase 2 data.
Patient BehaviorUp to 5% of US patients actively switch therapies every quarter, highlighting challenges with switching therapies.
Stock RecommendationAnalyst maintains an Underperform rating with a $14 price objective.
---
Ownership Overview
―
Insiders
7.24% Mutual Funds
71.83% Other Institutional Investors
20.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $15.00 and its highest was $33.00 in the past 12 months.
What is Pharvaris’s market cap?
Currently, no data Available
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Apr 24, 2025 which is in 153 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Nov 13, 2024. The company reported -$0.816 earnings per share for the quarter, missing the consensus estimate of -$0.628 by -$0.189.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris have?
Pharvaris has 54,007,710 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.816 in its last earnings report, missing expectations of -$0.628. Following the earnings report the stock price went up 2.545%.
Which hedge fund is a major shareholder of Pharvaris?
Among the largest hedge funds holding Pharvaris’s share is Viking Global Investors LP. It holds Pharvaris’s shares valued at 68M.
---
Pharvaris Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.29 (72.15% Upside)
$35.29 (72.15% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.99%
12-Months-Change
Fundamentals
Return on Equity
-58.16%
Trailing 12-Months
Asset Growth
94.95%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
---
PHVS Stock 12 Month Forecast
Average Price Target
$35.29
▲(72.15% Upside)
Technical Analysis
Best Analysts Covering PHVS
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+65.39%
reiterated a buy rating 3 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +65.39% per trade.
---